Sutliff V E, Rattan S, Gardner J D, Jensen R T
Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland 20892.
Am J Physiol. 1989 Aug;257(2 Pt 1):G226-34. doi: 10.1152/ajpgi.1989.257.2.G226.
By use of a highly enriched preparation of chief cells (greater than 90% pure) prepared from guinea pig stomach, the cholinergic receptors regulating pepsinogen secretion were studied. Each of five different muscarinic cholinergic agonists, but not the nicotinic cholinergic agonist nicotine, stimulated pepsinogen release. Carbamylcholine-stimulated pepsinogen release was inhibited by each of seven different cholinergic receptor antagonists with relative potencies of N-methylscopolamine greater than scopolamine = 4-diphenylacetoxy-N-methylpiperidine methiodide = atropine much greater than pirenzepine greater than AF-DX-116 much greater than tetraethylammonium. Binding of [N-methyl-3H]scopolamine ([3H]NMS) was time and temperature dependent, reversible, saturable, and specific. Analysis of [3H]NMS binding demonstrated a Kd of 1.3 nM for NMS with a binding capacity of 61 fmol/mg protein or 5,920 sites/chief cell. With the agonists carbamylcholine, acetylcholine, or muscarine, the receptor population could be divided into two classes of receptor sites: a class with high affinity (Kd, 12-53 microM) representing 73% of the binding sites and a class with low affinity (Kd, 2-5 mM) representing 27% of the binding sites. Each of the antagonists had equal affinity for both receptor populations. There was a close correlation between the ability of antagonists to inhibit [3H]NMS binding and carbamylcholine-stimulated pepsinogen release. Each agonist was 29- to 63-fold more potent at stimulating pepsinogen release than interacting with high-affinity receptors and 2,000- to 11,000-fold more potent than interacting with low-affinity receptors, suggesting spare receptors. Studies with the alkylating agent, propylbenzilylcholine mustard, demonstrated that there was a receptor reserve of 50-80%.(ABSTRACT TRUNCATED AT 250 WORDS)
利用从豚鼠胃制备的高度富集的主细胞制剂(纯度大于90%),研究了调节胃蛋白酶原分泌的胆碱能受体。五种不同的毒蕈碱型胆碱能激动剂中的每一种都能刺激胃蛋白酶原释放,但烟碱型胆碱能激动剂尼古丁则不能。七种不同的胆碱能受体拮抗剂中的每一种都能抑制氨甲酰胆碱刺激的胃蛋白酶原释放,其相对效力为:N-甲基东莨菪碱大于东莨菪碱 = 4-二苯基乙酰氧基-N-甲基哌啶甲基碘化物 = 阿托品远大于哌仑西平大于AF-DX-116远大于四乙铵。[N-甲基-3H]东莨菪碱([3H]NMS)的结合具有时间和温度依赖性、可逆性、饱和性及特异性。对[3H]NMS结合的分析表明,NMS的解离常数(Kd)为1.3 nM,结合容量为61 fmol/mg蛋白质或每个主细胞5920个位点。使用激动剂氨甲酰胆碱、乙酰胆碱或毒蕈碱时,受体群体可分为两类受体位点:一类具有高亲和力(Kd,12 - 53 μM),占结合位点的73%;另一类具有低亲和力(Kd,2 - 5 mM),占结合位点的27%。每种拮抗剂对这两类受体群体的亲和力相等。拮抗剂抑制[3H]NMS结合的能力与氨甲酰胆碱刺激的胃蛋白酶原释放之间存在密切相关性。每种激动剂刺激胃蛋白酶原释放的效力比与高亲和力受体相互作用时高29至63倍,比与低亲和力受体相互作用时高2000至11000倍,提示存在备用受体。用烷基化剂丙基苯甲酰胆碱氮芥进行的研究表明,受体储备为50 - 80%。(摘要截短于250字)